TCRXの企業概要
日中の時刻はETです。市場データは遅延する場合があります。
企業プロフィール
会社ウェブサイトTScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- 業界
- Biotechnology
- セクター
- Healthcare
- 本社
- US
- 最高経営責任者（CEO）
- Gavin MacBeath
- 上場以来
- 2021年7月16日
- 従業員
- 138
市場での位置
日中レンジ
現在 $0.2422
52週レンジ
現在 $0.2422
- 始値
- $0.24
- 前日終値
- $0.238
- 出来高
- 36.93万
- 0.47× 平均
- 平均出来高
- 77.84万
- 1日平均出来高
- 時価総額
- 1479.22万 USD
- ベータ
- 1.14
- 市場参照 1
- 50日平均
- $0.5264
- 平均以下（-53.99%）
- 200日平均
- $0.9172
- 平均以下（-73.59%）
